XML 46 R36.htm IDEA: XBRL DOCUMENT
v3.23.3

SEGMENT AND GEOGRAPHIC INFORMATION (Tables) | 9 Months Ended
--- | ---
Sep. 30, 2023
Segment Reporting [Abstract] |
Schedule of Net Sales and Profit by Segments | Net sales and profit by each reportable segment for the three and nine months ended September 30, 2023 and 2022 are as follows:
| Three Months Ended September 30, |  | Nine Months Ended September 30,
Dollars in thousands | 2023 |  | 2022 |  | 2023 |  | 2022
Segment Net Sales |  |  |  |  |  |  |
Codman Specialty Surgical | $ | 268,205 |  |  | $ | 249,796 |  |  | $ | 787,371 |  |  | $ | 754,967 |
Tissue Technologies | 114,216 |  |  | 135,395 |  |  | 357,163 |  |  | 404,677 |
Total revenues | $ | 382,421 |  |  | $ | 385,191 |  |  | $ | 1,144,534 |  |  | $ | 1,159,644 |
Segment Profit |  |  |  |  |  |  |
Codman Specialty Surgical | $ | 105,170 |  |  | $ | 105,717 |  |  | $ | 332,444 |  |  | $ | 308,073 |
Tissue Technologies | 31,789 |  |  | 59,754 |  |  | 92,132 |  | 175,273 |
Segment profit | 136,959 |  |  | 165,471 |  |  | 424,576 |  |  | 483,346 |
Amortization | (3,208) |  | (3,141) |  | (9,342) |  |  | (10,339)
Corporate and other | (107,158) |  |  | (97,281) |  |  | (339,755) |  | (301,927)
Operating income | $ | 26,593 |  |  | $ | 65,049 |  |  | $ | 75,479 |  |  | $ | 171,080 |
Total revenue by major geographic area consisted of the following:
| Three Months Ended September 30, |  | Nine Months Ended September 30,
Dollars in thousands | 2023 |  | 2022 |  | 2023 |  | 2022
United States | $ | 269,838 |  |  | $ | 282,016 |  |  | $ | 817,622 |  |  | $ | 832,714 |
Europe | 41,524 |  |  | 38,301 |  |  | 120,040 |  |  | 128,907 |
Asia Pacific | 48,777 |  |  | 42,774 |  |  | 146,956 |  |  | 133,856 |
Rest of World | 22,282 |  |  | 22,100 |  |  | 59,916 |  |  | 64,167 |
Total Revenues | $ | 382,421 |  |  | $ | 385,191 |  |  | $ | 1,144,534 |  |  | $ | 1,159,644 |
Schedule of Geographic Revenue by Area | Net sales and profit by each reportable segment for the three and nine months ended September 30, 2023 and 2022 are as follows:
| Three Months Ended September 30, |  | Nine Months Ended September 30,
Dollars in thousands | 2023 |  | 2022 |  | 2023 |  | 2022
Segment Net Sales |  |  |  |  |  |  |
Codman Specialty Surgical | $ | 268,205 |  |  | $ | 249,796 |  |  | $ | 787,371 |  |  | $ | 754,967 |
Tissue Technologies | 114,216 |  |  | 135,395 |  |  | 357,163 |  |  | 404,677 |
Total revenues | $ | 382,421 |  |  | $ | 385,191 |  |  | $ | 1,144,534 |  |  | $ | 1,159,644 |
Segment Profit |  |  |  |  |  |  |
Codman Specialty Surgical | $ | 105,170 |  |  | $ | 105,717 |  |  | $ | 332,444 |  |  | $ | 308,073 |
Tissue Technologies | 31,789 |  |  | 59,754 |  |  | 92,132 |  | 175,273 |
Segment profit | 136,959 |  |  | 165,471 |  |  | 424,576 |  |  | 483,346 |
Amortization | (3,208) |  | (3,141) |  | (9,342) |  |  | (10,339)
Corporate and other | (107,158) |  |  | (97,281) |  |  | (339,755) |  | (301,927)
Operating income | $ | 26,593 |  |  | $ | 65,049 |  |  | $ | 75,479 |  |  | $ | 171,080 |
Total revenue by major geographic area consisted of the following:
| Three Months Ended September 30, |  | Nine Months Ended September 30,
Dollars in thousands | 2023 |  | 2022 |  | 2023 |  | 2022
United States | $ | 269,838 |  |  | $ | 282,016 |  |  | $ | 817,622 |  |  | $ | 832,714 |
Europe | 41,524 |  |  | 38,301 |  |  | 120,040 |  |  | 128,907 |
Asia Pacific | 48,777 |  |  | 42,774 |  |  | 146,956 |  |  | 133,856 |
Rest of World | 22,282 |  |  | 22,100 |  |  | 59,916 |  |  | 64,167 |
Total Revenues | $ | 382,421 |  |  | $ | 385,191 |  |  | $ | 1,144,534 |  |  | $ | 1,159,644 |

X
- Definition Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 350 -SubTopic 20 -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482573/350-20-50-1 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 25 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-25 Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 22 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22 Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 30 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30 + Details
Name: | us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | us-gaap_SegmentReportingAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration